SynAging provides in vitro and in vivo models to test new symptomatic and neuroprotective treatments for Alzheimer’s dementia (AD). The AD models are based on the effects of a single injection of minute amounts of misfolded protein aggregates on synapses, the innate immune system, and resulting cognitive deficits in rodents.
Soluble oligomers (and fibrils) are prepared by SynAging from:
• amyloid-β peptides (AbO), or
• human tau-proteins (hTO)
in proprietary and confidential protocols resulting in the world-wide highest reproducibility. All preparations are validated by quality control before use in client projects and the performance of the controls is guaranteed by SynAging.
A number of clinical reference compounds and many clients’ compounds have been tested in SynAging’s models. The results of the clinical reference compounds were found to resemble findings from clinical use, suggesting translatability of SynAging's Alzheimer disease model results into the clinic.
Compound candidates can be tested and optimized in:
• in vitro assays using acutely isolated primary rodent neurons
• in vitro assays using acutely isolated primary astrocytes
• in vitro assays using iPS cell derived human neuronal cultures
• in vivo assays investigating treatment benefits for various cognitive domains in our various validated cognitive assays in mice
AD treatments can further be tested in general neurodegeneration models using various stimuli, such as excitotoxicity and oxidative stress.
Please see: Alzheimer’s Dementia in Science and Technology